Posted by Michael Wonder on 09 Aug 2022
Relmada Therapeutics receives FDA fast track designation for REL-1017 as a monotherapy for the treatment of major depressive disorder
9 August 2022 - Relmada Therapeutics today announced that the U.S. FDA has granted fast track designation to REL-1017, the Company's novel NMDA receptor channel blocker, as a monotherapy for the treatment major depressive disorder.
REL-1017, a new chemical entity and novel NMDA receptor channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of major depressive disorder.
